Yep it’s definitely Friday

Yep it’s definitely Friday

Once again, the weekend beckons and while we can’t speak for anyone else this should be a good one here in the beautiful city of Chicago. Yep it’s our annual air and water show which is pretty cool event, nothing quite like seeing the Blue Angles fly by your office window. Yet before the weekend gets here let’s review some of the wackier events that took place this week.

Novo Nordisk (NYSE: NVO) released results from their Sustain 7 trial which compared their long-acting GLP-1 semaglutide to Lilly’s (NYSE: LLY) Trulicity. Per the company’s press release;

“From a mean baseline HbA1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People treated with 1.0 mg semaglutide experienced a statistically significant and superior reduction of 1.8% compared with a reduction of 1.4% with 1.5 mg dulaglutide.”

“Furthermore, from a mean baseline body weight of 95 kg and a BMI of 33.5 kg/m2, people treated with 0.5 mg semaglutide experienced a statistically significant and superior weight loss of 4.6 kg compared to 2.3 kg with 0.75 mg dulaglutide. People treated with 1.0 mg semaglutide experienced a statistically significant and superior weight loss of 6.5 kg compared to 3.0 kg with 1.5 mg dulaglutide.”

First, we are not surprised by the results as semaglutide has looked impressive in other trials. However, we aren’t as thrilled as some appear to be as to what this means when semaglutide goes head to head with Trulicity in the marketplace. There is no question needs a hit and at first glance semaglutide looks to be on track to become one, that is until you consider the highly competitive nature of the GLP-1 market which is becoming just as rough and tumble as the insulin market.

Next semaglutide is still awaiting FDA approval allowing Lilly the luxury of building greater share for Trulicity Which basically means that when semaglutide does get here Novo will have to use price/rebates/discounts to gain formulary access. Which of course means that Lilly will fight back. Simply put the long-acting GLP-1 market is about to face a price war. Just in case anyone has forgotten data is meaningless and this is and will always be about money.

Speaking of money, it looks like the folks at MyDario are looking to raise another $4 million through a private placement. While Senseonics is looking to raise another $25 million selling another 11.6 million shares priced at $2.15 per share. More than likely both companies will be successful in their efforts as if there is one constant in this wacky world its investors like to throw money away. Of the two Senseonics is the better play as many believe that their partner Roche will eventually buy them.

Sticking with the money angle Tandem (NADSAQ; TNDM) announced this week they have enrolled the first patients in a pivotal trial. Per a company issued press release;

“Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced enrollment of the first patients in an at-home pivotal trial for its t:slim X2™ Insulin Pump using Tandem’s predictive low glucose suspend (PLGS) technology. The insulin pump system, which uses an integrated Dexcom G5® Mobile Continuous Glucose Monitor (CGM), is designed to suspend insulin delivery when low blood glucose is predicted and subsequently resume insulin delivery when glucose levels begin to rise.”

Now we hate to dump on our beleaguered friends at Tandem but this is hardly innovative and will do nothing to solve their major financial problems. As we noted just yesterday management remains oblivious to the impending doom that is about to descend upon them. The reality is the doomsday clock is ticking and midnight is fast approaching.

Lastly since this is Friday and happy hour beckons here is a piece of news that will add a few shots to the menu. We have heard from several sources that Medtronic (NYSE: MDT) is telling suppliers to … wait for it … give patients the Dexcom (NASDAQ: DXCM) system because they cannot supply their new Enlite sensor. We’d say this is stunning news but as we have been saying a lot lately there is very little news that shocks us anymore. This is after all the wacky world of diabetes where anything can and usually does happen.

Have a great weekend everyone.